Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,770
Change Today -30.00 / -1.67%
Volume 100.7K
KMDA On Other Exchanges
Symbol
Exchange
Tel Aviv
NASDAQ GS
Stuttgart
As of 9:24 AM 04/19/15 All times are local (Market data is delayed by at least 15 minutes).

kamada ltd (KMDA) Snapshot

Open
$1,799
Previous Close
$1,800
Day High
$1,801
Day Low
$1,767
52 Week High
04/24/14 - $5,138
52 Week Low
11/25/14 - $1,160
Market Cap
638.4M
Average Volume 10 Days
62.4K
EPS TTM
$-0.35
Shares Outstanding
36.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAMADA LTD (KMDA)

kamada ltd (KMDA) Related Businessweek News

No Related Businessweek News Found

kamada ltd (KMDA) Details

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. Its respiratory disease products, including Glassia used in augmentation therapy for patients with emphysema secondary to congenital alpha-1 antitrypsin deficiency; and Bramitob to manage chronic pulmonary infection. The company’s immunoglobulin products include KamRAB for prophylaxis against rabies infection; KamRho(D)IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; Snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. In addition, it provides critical care products, such as Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of proper level in the patient’s blood plasma. Further, the company offers Heparin Lock Flush to maintain patency of indwelling IV catheter; Human Transferrin for diagnostic assays and cell cultures; and Kamacaine 0.5% used as anesthesia or analgesia for surgery, obstetrical procedures, and diagnostic and therapeutic procedures, as well as spinal anesthesia for surgery. Additionally, it offers coagulation factors, including Factor VIII, Factor IX, and Bupivacaine. The company also develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, chronic obstructive pulmonary disease, graft-versus-host diseases, and transplantations. It has a collaboration partnership with PARI and Baxter Healthcare Corporation. The company markets its products through strategic partners in the United States and Europe; and distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

Founded in 1990

kamada ltd (KMDA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $1.5M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $347.0K
Vice President of Operations and Plant Manage...
Total Annual Compensation: $232.0K
Vice President of Clinical Development & IP
Total Annual Compensation: $177.0K
Vice President of Research and Development
Total Annual Compensation: $199.0K
Compensation as of Fiscal Year 2013.

kamada ltd (KMDA) Key Developments

Kamada Ltd. Gets European Orphan Drug Designation for its Alpha-1 Antitrypsin to Treat Graft-Versus-Host Disease

Kamada Ltd. announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA), has designated the company’s proprietary human intrevenous (IV) Alpha-1 Antitrypsin (AAT) as an orphan medicinal product to treat Graft-versus-host disease (GvHD). In October 2014 Kamada received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for its AAT by IV to treat GvHD. Preliminary human and animal studies indicate that AAT may be able to treat and reduce the severity of GvHD, which is one of the key, life-threatening complications of allogeneic stem cell transplantation. GvHD is an immunologically-based disease that may result in significant damage to multiple organs and tissues such as the liver, gastrointestinal tract, skin and mucosal membranes. Tissue destruction also leads to increased inflammatory signals, perpetuating and augmenting the disease process by contributing to the cytokine storm that fuels GvHD even further and, thereby, the damage continues and its intensity is increased. In recent years, AAT has been investigated extensively and found to have anti-inflammatory, tissue-protective, immune-modulatory and anti-apoptotic properties in direct or indirect consequence of its underlying anti-protease capabilities. These properties may attenuate inflammation by lowering levels of pro-inflammatory mediators such as cytokines, chemokines and proteases that are associated with this severe disease. Kamada’s AAT therapy is being investigated in a clinical U.S. Phase 1/2 study that is evaluating 24 GvHD patients with inadequate response to steroid treatment following allogeneic bone-marrow stem cell transplant. The patients are enrolled into 4 dose cohorts, in which they receive up to 8 doses of Kamada’s AAT. The study is being conducted by the Fred Hutchinson Cancer Research Center in Seattle in cooperation with Baxter International. Interim results from this study were presented in a poster at the American Society of Hematology Annual Meeting in December 2014. Preliminary results indicated that continuous administration of AAT as therapy for steroid-resistant gut GvHD is feasible in the subject population. Indication of healing of the bowel mucosa was seen in a decrease in diarrhea, in a decrease in intestinal AAT loss, and improvement in endoscopic evaluation. Additionally, in the preliminary results AAT administration suppressed serum levels of pro-inflammatory cytokines and interfered with GvHD biomarkers.

Kamada Appoints Eran Schenker as Vice President-Medical Director

Kamada Ltd. announced that the company has strengthened its senior leadership team with the appointment of Eran Schenker, M.D. to the newly created position of Vice President-Medical Director. Dr. Schenker will report to David Tsur, co-founder and CEO of Kamada. Dr. Schenker joins Kamada with more than 15 years of experience in international medical affairs and business development for biotechnology and pharmaceutical companies. Prior to Kamada, from 2007 to 2014, Dr. Schenker was with Neurim Pharmaceuticals, where he initially served as the Medical Director and Business Development Manager and later as Vice President, where he completed the launch of the company's CNS product in more than 40 countries.

Kamada Ltd. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:10 PM

Kamada Ltd. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:10 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KMDA:IT 1,770.00 -30.00

KMDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €40.43 EUR -1.38
View Industry Companies
 

Industry Analysis

KMDA

Industry Average

Valuation KMDA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAMADA LTD, please visit www.kamada.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.